Matches in SemOpenAlex for { <https://semopenalex.org/work/W591762953> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W591762953 abstract "Although the main reason for the lack of distinct dose-response and -toxicity relationships for anti-cancer agents is due to variability in pharmacodynamics, variability in pharmacokinetics may also contribute. Hence, not only describing and quantifying the relationship between pharmacokinetics and dose-limiting toxicities, but characterising the pharmacokinetics and its associated variability are of obvious importance in the process of developing dosing strategies for anti-cancer regimens. The aim of this thesis was to characterize the pharmacokinetics of fluorouracil (5-FU), epirubicin (EPI), 4-hydroxycyclophosphamide (4-OHCP), docetaxel (DTX) and busulphan (Bu) and, additionally, the relationship between the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide and epirubicin-docetaxel regimens. The pharmacokinetics of the combination EPI-DTX (ED) was studied in rats and patients, whereas the pharmacokinetics of Bu and 5-FU-EPI-4-OHCP (FEC) and haematological toxicity of the FEC and ED regimens was studied in patients only. All data analysis was performed using the NONMEM program. For all studied drugs, except 4-OHCP, course-to-course variability was found to be less than the inter-individual variability in the pharmacokinetic parameters and thereby therapeutic drug monitoring (TDM) may be a suitable approach for dose individualisation of all studied drugs, except CP. The development of haematological toxicity after treatment was described well by a semi-physiological model. In the case of the ED regimen, the model appeared to be able to estimate the respective contribution of EPI and DTX to the bone marrow toxicity. Thus, using the final PK-PD model in the individualisation process may further improve the probability of prescribing the most appropriate dose regimen for a patient early in the treatment period. A dosing program was constructed by implementing the final Bu population model into Excel, which resulted in a flexible and easy to use dosing tool. Similar programs may be constructed and used for dose individualisation of other anti-cancer drugs." @default.
- W591762953 created "2016-06-24" @default.
- W591762953 creator A5063646932 @default.
- W591762953 date "2002-01-01" @default.
- W591762953 modified "2023-09-24" @default.
- W591762953 title "Pharmacokinetics and Pharmacodynamics of Anti-Cancer Regimens : Emphasis on Busulphan and the Combination Therapies Epirubicin-Docetaxel and Fluorouracil-Epirubicin-Cyclophosphamide" @default.
- W591762953 hasPublicationYear "2002" @default.
- W591762953 type Work @default.
- W591762953 sameAs 591762953 @default.
- W591762953 citedByCount "0" @default.
- W591762953 crossrefType "journal-article" @default.
- W591762953 hasAuthorship W591762953A5063646932 @default.
- W591762953 hasConcept C111113717 @default.
- W591762953 hasConcept C112705442 @default.
- W591762953 hasConcept C126322002 @default.
- W591762953 hasConcept C143998085 @default.
- W591762953 hasConcept C2776239304 @default.
- W591762953 hasConcept C2776694085 @default.
- W591762953 hasConcept C2776755627 @default.
- W591762953 hasConcept C2780456651 @default.
- W591762953 hasConcept C2780835546 @default.
- W591762953 hasConcept C2781190966 @default.
- W591762953 hasConcept C29730261 @default.
- W591762953 hasConcept C71924100 @default.
- W591762953 hasConcept C98274493 @default.
- W591762953 hasConceptScore W591762953C111113717 @default.
- W591762953 hasConceptScore W591762953C112705442 @default.
- W591762953 hasConceptScore W591762953C126322002 @default.
- W591762953 hasConceptScore W591762953C143998085 @default.
- W591762953 hasConceptScore W591762953C2776239304 @default.
- W591762953 hasConceptScore W591762953C2776694085 @default.
- W591762953 hasConceptScore W591762953C2776755627 @default.
- W591762953 hasConceptScore W591762953C2780456651 @default.
- W591762953 hasConceptScore W591762953C2780835546 @default.
- W591762953 hasConceptScore W591762953C2781190966 @default.
- W591762953 hasConceptScore W591762953C29730261 @default.
- W591762953 hasConceptScore W591762953C71924100 @default.
- W591762953 hasConceptScore W591762953C98274493 @default.
- W591762953 hasLocation W5917629531 @default.
- W591762953 hasOpenAccess W591762953 @default.
- W591762953 hasPrimaryLocation W5917629531 @default.
- W591762953 hasRelatedWork W144668201 @default.
- W591762953 hasRelatedWork W1608291762 @default.
- W591762953 hasRelatedWork W1788320651 @default.
- W591762953 hasRelatedWork W1879970445 @default.
- W591762953 hasRelatedWork W1974814035 @default.
- W591762953 hasRelatedWork W1975538968 @default.
- W591762953 hasRelatedWork W1998800586 @default.
- W591762953 hasRelatedWork W2026738950 @default.
- W591762953 hasRelatedWork W2028100471 @default.
- W591762953 hasRelatedWork W2033203975 @default.
- W591762953 hasRelatedWork W2033397182 @default.
- W591762953 hasRelatedWork W2086139797 @default.
- W591762953 hasRelatedWork W2087208740 @default.
- W591762953 hasRelatedWork W2095248699 @default.
- W591762953 hasRelatedWork W2112163451 @default.
- W591762953 hasRelatedWork W2151573345 @default.
- W591762953 hasRelatedWork W2733538150 @default.
- W591762953 hasRelatedWork W2747566431 @default.
- W591762953 hasRelatedWork W2916073154 @default.
- W591762953 hasRelatedWork W647228126 @default.
- W591762953 isParatext "false" @default.
- W591762953 isRetracted "false" @default.
- W591762953 magId "591762953" @default.
- W591762953 workType "article" @default.